BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Dewan B, Chimata R. An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition. World J Gastrointest Pharmacol Ther 2010; 1(5): 112-118 [PMID: 21577305 DOI: 10.4292/wjgpt.v1.i5.112]
URL: https://www.wjgnet.com/1007-9327/full/v1/i5/112.htm
Number Citing Articles
1
Komal Parmar, Nitisha Yagneshwari. Gastroretentive Chronopharmaceutical Formulation of Lafutidine for Early Morning Acid BreakthroughPharmacophore 2022; 13(5): 1 doi: 10.51847/KwfMN53pu5
2
Satish Patil, Gokul S. Talele. Gastroretentive mucoadhesive tablet of lafutidine for controlled release and enhanced bioavailabilityDrug Delivery 2015; 22(3): 312 doi: 10.3109/10717544.2013.877099
3
M. Yadav, V. Trivedi, V. Upadhyay, G. Shah, H. Shah, A. Upadhyay, S. Goswami, P. S. Shrivastav. Sensitive, selective and rapid determination of lafutidine in human plasma by solid phase extraction-liquid chromatography-tandem mass spectrometryJournal of Analytical Chemistry 2014; 69(5): 448 doi: 10.1134/S1061934814050116
4
Shihong Li, Mingzhen Xu, Huqun Li, Juan Du, Weiyong Li. Pharmacokinetic Properties of Oral Lafutidine Tablets and the Effect of Food on its Pharmacokinetics in Healthy Chinese SubjectsAdvances in Therapy 2016; 33(10): 1704 doi: 10.1007/s12325-016-0383-9